Case Background:
This is a federal securities fraud class action brought on behalf of all persons who purchased or otherwise acquired Alkermes Public Limited Company (“Alkermes”) common stock between July 31, 2014 and November 1, 2018, both dates inclusive (the “Class Period”).
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the U.S. Food and Drug Administration (“FDA”) had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.
Current Status of Case:
On July 9, 2019, Lead Plaintiff filed an Amended Consolidated Complaint. Defendants filed a Motion to Dismiss the Amended Complaint on January 17, 2020. On February 26, 2021, the Defendants’ Motion was granted and the action was dismissed in its entirety. Lead Plaintiff filed a Notice of Appeal on March 26, 2021. The District Court’s Judgment was affirmed on December 28, 2021. This action has concluded.
f you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.